- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03490825
Aging Program Project Grant 6 (PPG6)
Enhancing Circadian Signal to Improve Cardiometabolic Function in Aging
This study aims to enhance circadian signals to improve cardiometabolic functions in older adults though meal timing interventions and melatonin supplements. Cardiometabolic disease (CMD) is prevalent among older adults, but despite vigorous research to prevent it, it remains on of the greatest public health challenges. Previous research has shown that extended overnight fasting and melatonin supplements may enhance circadian signals which in turn would enhance cardiometabolic function in older adults.
This study will place subjects in one of four intervention groups, 1) Meal timing + Melatonin, 2) Meal timing + Placebo, 3) Melatonin, or 4) Placebo in order test out the effects of meal timing and melatonin both separately and together and cardio metabolic functions. The study will explore the effects of these interventions in acute-based setting and extended-based settings. This will allow us to test out the hypotheses of the study that meal timing can improve amplitude of circadian signals and improve cardiometabolic functions and sleep quality as well as melatonin improving cardiometabolic function and sleep quality. Finally, we will determine if the the addition of melatonin will further enhance the effects of the meal timing intervention for improving cardiometabolic function and sleep.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Phyllis Zee, MD, PhD
- Phone Number: 312-503-4409
- Email: p-zee@northwestern.edu
Study Contact Backup
- Name: Kathyrn Reid, PhD
- Phone Number: 312-503-1528
- Email: k-reid@northwestern.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Kathyrn Reid, PhD
- Phone Number: 312-503-1528
- Email: k-reid@northwestern.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Older adults 55-75 years old.
- Females must be post-menopausal.
- BMI 25-45
- Regular eating schedule (consuming at least 2 meals/day) and sleeping schedules (deviation of ≤ 2 hours in daily mid-sleep time).
- Self-report sleep duration of ≥ 6.5 hours.
- Habitual mid-sleep time of 1-5 am.
- Habitual time in bed less than 9 hours
- HbA1c <6.5
- Habitual overnight fast of ≤ 13 hour (Determined by a mean overnight fast ≤ 13 hours over 3 days of self-monitoring of food intake)
Exclusion Criteria:
- History or current diagnosis of a primary sleep disorder (Chronic insomnia, restless leg syndrome, parasomnias, sleep apnea).
- AHI ≥30
- History of anemia.
- Diagnosis of diabetes or currently on any medications for diabetes.
- Endocrine dysfunction including PCOS.
- History of cognitive or other neurological disorders.
- History of DSM-V criteria for any major psychiatric disorder.
- Beck depression Index (BDI) of ≥16 indicating moderate depression.
- Mini mental status Exam <26 indicating cognitive impairment.
- Unstable or serious medical conditions.
- Individuals with pacemakers, defibrillators, mediation pumps, or any other implanted device.
- Any GI disease that requires dietary adjustment.
- Current or use within last month of melatonin.
- Current use of psychoactive, hypnotic, stimulants, or pain medications.
- Current use of hormone replacement therapy.
- Shift work or other self-imposed irregular sleep schedules.
- History of habitual smoking (≥6 cigarettes/week).
- Caffeine consumption >400 mg/day.
- Medically managed or self-reported weight loss program within past 6 months.
- Bariatric weight loss surgery.
- Blindness or visual impairment other than glasses.
- Allergic to heparin.
- Adults unable to consent will be excluded.
- Pregnant women will be excluded.
- Prisoners will be excluded.
- Individuals who are not yet adults (infants, children, teenagers) will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Meal timing + Melatonin
This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time.
This arm will also include a 1mg melatonin supplementation given daily during the intervention.
|
Melatonin (1mg) will be administered daily during the intervention.
Melatonin capsules will be obtained from Life Extension (Ft.
Lauderdale, FL).
The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical.
We have worked with this IDP on other projects.
The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
Other Names:
|
Experimental: Meal timing + Placebo
This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time.
This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
|
Subjects are instructed to maintain an extended overnight fasting period of 12-16 hours.
Other Names:
Placebo will be administered daily during the intervention.
The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical.
We have worked with this IDP on other projects.
The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
|
Experimental: Melatonin
This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake.
No EOF will be imposed.
This arm will include a 1mg melatonin supplementation given daily during the intervention.
|
Melatonin (1mg) will be administered daily during the intervention.
Melatonin capsules will be obtained from Life Extension (Ft.
Lauderdale, FL).
The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical.
We have worked with this IDP on other projects.
The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
Subjects are instructed to maintain their habitual meal timing.
Other Names:
|
Placebo Comparator: Placebo
This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake.
No EOF will be imposed.
This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
|
Placebo will be administered daily during the intervention.
The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical.
We have worked with this IDP on other projects.
The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
Subjects are instructed to maintain their habitual meal timing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Matsuda Index
Time Frame: 8 weeks
|
The matsuda index of whole body index sensitivity will be calculated to explore the effect of sleep and circadian rhythms on the relationship between EOF, melatonin, and CMD.
|
8 weeks
|
Nocturnal Blood Pressure Dipping
Time Frame: 8 weeks
|
Defined as a ratio of sleep blood pressure to wake blood pressure less than 0.90.
|
8 weeks
|
Melatonin Amplitude
Time Frame: 8 weeks
|
The melatonin amplitude will be calculated to determine the effects of the interventions on sleep and CMD outcomes.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Phyllis Zee, MD, PhD, Northwestern University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00206014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Improving Cardiometabolic Outcomes in Older Adults
-
Northwestern UniversityRecruiting
-
Nova Southeastern UniversityCompletedOlder Persons Interested in Improving Their Brain HealthUnited States
-
University of Alabama at BirminghamCompletedPhysical Fitness in Older AdultsUnited States
-
University of ZurichCompletedMotivation in Healthy Older AdultsSwitzerland
-
University of Lausanne HospitalsUniversité Catholique de Louvain; Mindmaze SA; Centre de Recherche de l'Institut... and other collaboratorsCompletedCognitive Decline Prevention in Robust Older Adults | Cognitive Decline Prevention in Pre-frail Older Adults | Physical Decline Prevention in Robust Older Adults | Physical Decline Prevention in Pre-frail Older AdultsBelgium, Canada, Switzerland
-
Weill Medical College of Cornell UniversityNational Institute on Aging (NIA)Completed
-
University of ExtremaduraRecruiting
-
The Hong Kong Polytechnic UniversityUniversity of California, Berkeley; University of WaterlooCompletedVision, Balance and Falls in Older AdultsChina
-
Universitaire Ziekenhuizen KU LeuvenCompletedEffects of Strength Training in Older AdultsBelgium
-
National University Hospital, SingaporeSingapore General HospitalCompletedCataract Surgery | Stress Levels | Music Improving Outcomes in Cataract SurgerySingapore
Clinical Trials on Melatonin 1 mg
-
Utrecht UniversityCompletedPharmacokinetics of MelatoninNetherlands
-
Ain Shams UniversityCompletedCerebral Palsy | Growth | Children, Only | MelatoninEgypt
-
Aragon Institute of Health SciencesMinisterio de Sanidad, Servicios Sociales e IgualdadUnknownSeptic Shock | Severe SepsisSpain
-
Khon Kaen UniversityUnknownPharmacokinetics of MelatoninThailand
-
Providence Health & ServicesCompletedRelapsing Remitting Multiple SclerosisUnited States
-
Lars Peter Holst AndersenUniversity of CopenhagenCompleted
-
Cairo UniversityCompleted
-
Khon Kaen UniversityThailand Research Fund; Srinagarind Hospital, Khon Kaen University; Khon Kaen... and other collaboratorsCompletedAdvanced Stage CancerThailand
-
Nalaka GooneratneNational Center for Complementary and Integrative Health (NCCIH)CompletedSleep Initiation and Maintenance DisordersUnited States
-
All India Institute of Medical Sciences, BhubaneswarCompleted